scholarly journals Computer aided detection of imaging biomarkers for Alzheimer's disease

2021 ◽  
Vol 12 (3) ◽  
pp. 108
Author(s):  
G. Sateesh Babu ◽  
B.S. Mahanand
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Imaging Biomarkers ◽  
Computer Aided Detection ◽  
Computer Aided

Computer-aided methods for 3-D visualization of serial sections and thick biological specimens

1992 ◽  
Vol 50 (2) ◽  
pp. 1060-1061
Author(s):  
Mark Ellisman ◽  
Maryann Martone ◽  
Gabriel Soto ◽  
Eleizer Masliah ◽  
David Hessler ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Three Dimensional ◽  
Neuritic Plaque ◽  
Dimensional Structure ◽  
Data Sets ◽  
Molecular Physiology ◽  
Research Activities ◽  
Computer Aided ◽  
Dimensional Reconstruction

Structurally-oriented biologists examine cells, tissues, organelles and macromolecules in order to gain insight into cellular and molecular physiology by relating structure to function. The understanding of these structures can be greatly enhanced by the use of techniques for the visualization and quantitative analysis of three-dimensional structure. Three projects from current research activities will be presented in order to illustrate both the present capabilities of computer aided techniques as well as their limitations and future possibilities.The first project concerns the three-dimensional reconstruction of the neuritic plaques found in the brains of patients with Alzheimer's disease. We have developed a software package “Synu” for investigation of 3D data sets which has been used in conjunction with laser confocal light microscopy to study the structure of the neuritic plaque. Tissue sections of autopsy samples from patients with Alzheimer's disease were double-labeled for tau, a cytoskeletal marker for abnormal neurites, and synaptophysin, a marker of presynaptic terminals.

Computer aided diagnosis of Alzheimer’s disease using component based SVM

2011 ◽  
Vol 11 (2) ◽  
pp. 2376-2382 ◽  
Author(s):  
I.A. Illán ◽  
J.M. Górriz ◽  
M.M. López ◽  
J. Ramírez ◽  
D. Salas-Gonzalez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Computer Aided Diagnosis ◽  
Computer Aided ◽  
Aided Diagnosis

SUBJECTIVE COGNITIVE DECLINE, LONGITUDINAL COGNITIVE PERFORMANCE, AND IMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER’S DISEASE

2017 ◽  
Vol 13 (7) ◽  
pp. P176
Author(s):  
Rebecca Amariglio ◽  
Rachel F. Buckley ◽  
Beth C. Mormino ◽  
Cathy Wang ◽  
Sarah L. Aghjayan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Cognitive Performance ◽  
Imaging Biomarkers ◽  
Subjective Cognitive Decline ◽  
Preclinical Alzheimer’S Disease

scholarly journals Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease

2021 ◽  
Vol 7 (1) ◽  
pp. eabb0457
Author(s):  
Yu-Hui Liu ◽  
Jun Wang ◽  
Qiao-Xin Li ◽  
Christopher J. Fowler ◽  
Fan Zeng ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Plasma Levels ◽  
Imaging Biomarkers ◽  
Amino Terminus ◽  
Cross Sectional ◽  
Naturally Occurring ◽  
Β Amyloid ◽  
Naturally Occurring Antibodies

The pathological relevance of naturally occurring antibodies to β-amyloid (NAbs-Aβ) in Alzheimer’s disease (AD) remains unclear. We aimed to investigate their levels and associations with Aβ burden and cognitive decline in AD in a cross-sectional cohort from China and a longitudinal cohort from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. NAbs-Aβ levels in plasma and cerebrospinal fluid (CSF) were tested according to their epitopes. Levels of NAbs targeting the amino terminus of Aβ increased, and those targeting the mid-domain of Aβ decreased in both CSF and plasma in AD patients. Higher plasma levels of NAbs targeting the amino terminus of Aβ and lower plasma levels of NAbs targeting the mid-domain of Aβ were associated with higher brain amyloidosis at baseline and faster cognitive decline during follow-up. Our findings suggest a dynamic response of the adaptive immune system in the progression of AD and are relevant to current passive immunotherapeutic strategies.

scholarly journals Imaging and Molecular Mechanisms of Alzheimer’s Disease: A Review

2018 ◽  
Vol 19 (12) ◽  
pp. 3702 ◽  
Author(s):  
Grazia Femminella ◽  
Tony Thayanandan ◽  
Valeria Calsolaro ◽  
Klara Komici ◽  
Giuseppe Rengo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Multimodal Imaging ◽  
Molecular Mechanisms ◽  
Imaging Techniques ◽  
Structural Mri ◽  
Imaging Biomarkers ◽  
Significant Burden ◽  
Made In

Alzheimer’s disease is the most common form of dementia and is a significant burden for affected patients, carers, and health systems. Great advances have been made in understanding its pathophysiology, to a point that we are moving from a purely clinical diagnosis to a biological one based on the use of biomarkers. Among those, imaging biomarkers are invaluable in Alzheimer’s, as they provide an in vivo window to the pathological processes occurring in Alzheimer’s brain. While some imaging techniques are still under evaluation in the research setting, some have reached widespread clinical use. In this review, we provide an overview of the most commonly used imaging biomarkers in Alzheimer’s disease, from molecular PET imaging to structural MRI, emphasising the concept that multimodal imaging would likely prove to be the optimal tool in the future of Alzheimer’s research and clinical practice.

scholarly journals Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to

2018 ◽  
Vol 107 ◽  
pp. 169-177 ◽  
Author(s):  
Adriane Dallanora Henriques ◽  
Andrea Lessa Benedet ◽  
Einstein Francisco Camargos ◽  
Pedro Rosa-Neto ◽  
Otávio Toledo Nóbrega
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Imaging Biomarkers

Research on Computer-Aided Diagnosis of Alzheimer’s Disease Based on Heterogeneous Medical Data Fusion

2019 ◽  
Vol 33 (05) ◽  
pp. 1957001
Author(s):  
Yin Dai ◽  
Daoyun Qiu ◽  
Yang Wang ◽  
Sizhe Dong ◽  
Hong-Li Wang
Keyword(s):  
Neural Network ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Convolutional Neural Network ◽  
Effective Means ◽  
Computer Aided Diagnosis ◽  
Test Results ◽  
Back Propagation Algorithm ◽  
Computer Aided ◽  
Aided Diagnosis

Alzheimer’s disease is the third most expensive disease, only after cancer and cardiopathy. It is also the fourth leading cause of death in the elderly after cardiopathy, cancer, and cerebral palsy. The disease lacks specific diagnostic criteria. At present, there is still no definitive and effective means for preclinical diagnosis and treatment. It is the only disease that cannot be prevented and cured among the world’s top ten fatal diseases. It has now been proposed as a global issue. Computer-aided diagnosis of Alzheimer’s disease (AD) is mostly based on images at this stage. This project uses multi-modality imaging MRI/PET combining with clinical scales and uses deep learning-based computer-aided diagnosis to treat AD, improves the comprehensiveness and accuracy of diagnosis. The project uses Bayesian model and convolutional neural network to train experimental data. The experiment uses the improved existing network model, LeNet-5, to design and build a 10-layer convolutional neural network. The network uses a back-propagation algorithm based on a gradient descent strategy to achieve good diagnostic results. Through the calculation of sensitivity, specificity and accuracy, the test results were evaluated, good test results were obtained.

Structural, Functional, and Molecular Neuroimaging Biomarkers for Alzheimer’s Disease

2013 ◽  
pp. 821-825
Author(s):  
James B. Brewer ◽  
Jorge Sepulcre ◽  
Keith A. Johnson
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cognitive Impairment ◽  
Neurodegenerative Disorders ◽  
Brain Dysfunction ◽  
Imaging Biomarkers ◽  
Neurocognitive Evaluation ◽  
Neuroimaging Biomarkers

Advances in quantitative structural, functional, and molecular neuroimaging have provided new tools for objective, in vivo, assessment of critical aspects of Alzheimer’s disease and other neurodegenerative disorders. Measures of brain atrophy or brain dysfunction, coupled with measures of disease-linked pathology, might complement the history, physical and neurocognitive evaluation of patients and thereby improve predictive prognosis, especially at early stages of cognitive impairment where neurodegenerative etiology is less certain. Such imaging biomarkers are currently used in nearly all clinical trials of therapeutic agents for Alzheimer’s disease and are increasingly incorporated into clinical practice. In this chapter, imaging biomarkers are introduced and discussed to familiarize the reader with their potential research and clinical uses.

Sign in / Sign up

Export Citation Format

Share Document